Colonoscopy, endoscopy, fecal calprotectin, CRP, imaging, intestinal ultrasound, and monitoring research.
Page 26 of 33 · 1559 articles
This real-world, multicenter study suggests risankizumab can induce clinical and steroid-free remission and mucosal healing in many patients with Crohn disease who previously failed advanced therapies, which may be...
Rheumatological EIMs (notably joint inflammation) are frequent in IBD and affect quality of life; inconsistent definitions and lack of validated PROs make it harder for patients and clinicians to understand and compare...
Faster, more accurate capsule endoscopy reading could shorten diagnostic delays and reduce missed small‑bowel lesions in Crohn’s disease. For busy clinics, an AI assistant could cut review time and help less‑experienced...
This trial explores whether oral ozanimod can induce and maintain remission in children and adolescents with moderate to severe ulcerative colitis who have not responded to standard therapies. Pediatric-specific evidence...
Risk-prediction tools like CDPATH™ could help people with Crohn’s disease and their doctors identify higher or lower short-term risk of complications and guide treatment conversations. This study tests how the tool...
Patients with UC often take multiple medicines that rely on CYP enzymes. This study is checking if afimkibart affects how those drugs are processed, which could matter for safety or dosing if the drug proceeds in...
A validated pre-endoscopic model could help estimate UC disease extent before colonoscopy, aiding clinical triage and planning without replacing endoscopy.
If validated, an early drop in fecal calprotectin could help identify patients on biologic therapy who are likely to achieve mucosal healing without waiting for invasive endoscopy, allowing earlier decisions about...
Early intestinal ultrasound may predict one-year endoscopic remission in Crohn's disease, offering a noninvasive tool to guide treatment decisions and possibly reduce the need for some colonoscopies.
KTS can mimic ulcerative colitis with bloody diarrhea and colonic vascular lesions, so awareness may prevent misdiagnosis and guide appropriate multidisciplinary care. Early recognition can help address bleeding, anemia,...
If fecal GP2 reliably reflects UC activity and microbial changes, it could become a noninvasive marker to track inflammation or to study disease mechanisms that differ between UC and CD.
The 1955 Truelove and Witts criteria do not account for patients already on modern outpatient therapies. Updated consensus criteria could change how ASUC is recognized and triaged in current clinical practice.
A rare but serious colitis linked to ocrelizumab is described and managed successfully with ciclosporin in a steroid‑refractory case; this may be relevant to clinicians caring for patients on B‑cell–depleting therapy.
Guidelines recommend treating objective inflammation even when symptoms are mild because untreated disease can cause complications; the article describes escalation to risankizumab due to endoscopic inflammation, high...
If confirmed, antibody signatures detectable years before symptoms could help identify people at higher risk for IBD and improve understanding of how the disease begins — a step toward earlier diagnosis or future...
Real-world data show how mirikizumab performs outside clinical trials, especially in patients previously exposed to multiple advanced therapies. That can help patients and clinicians weigh expectations for effectiveness...
Identifying patients at higher risk of hospitalization earlier could help clinicians target monitoring or treatment changes before clinical deterioration. Standard lab reference ranges may miss meaningful within-person...
This study suggests tofacitinib may work quickly as a rescue option for biologic‑naive patients with steroid‑refractory ASUC and that many achieved steroid‑free remission by 24 weeks — information that could matter when...
An externally validated, simple prediction score could help identify patients unlikely to need early aggressive treatment and inform shared decision-making about monitoring and therapy.
Dietary therapy (CDED + PEN) was associated with longer remission when families adhered well; since adherence varies, support from a dietitian matters for keeping children in remission.
This paper systematically catalogs drugs that have been reported with new or worsening IBD in two large pharmacovigilance databases. Knowing which medications generate strong reporting signals can help clinicians and...
Active IBD was linked to higher risk of RSV infection and more severe respiratory outcomes in this large observational study. That could be relevant for prevention and monitoring during periods of active disease.
Subcutaneous infliximab could offer children with IBD a more convenient dosing route with higher, steadier drug levels while maintaining remission. Insurance and labeling barriers affected access in this US cohort.
Strictures raise the risk that food will get stuck and cause a dangerous blockage. Simple changes to texture, portion size, and eating habits can lower that risk and help you keep a varied diet.
For patients and clinicians facing steroid- and infliximab-refractory acute severe ulcerative colitis, upadacitinib may be a third-line medical option that can produce rapid symptom and CRP improvement and allow some...
Identifies a redox-sensitive NOX1–ROS–IκBζ pathway that may sustain intestinal inflammation in IBD and points to a new molecular target for future therapies.
LCH can present like perianal Crohn's disease and may be missed if biopsies and molecular testing are not performed. Correct diagnosis changes treatment and prompts systemic staging for other malignancies.
The study found disease-specific antibody changes years before IBD diagnosis, suggesting possible early biomarkers and new clues about how Crohn's disease and ulcerative colitis begin.
FUT2 connects genetics, mucosal sugars, and the gut microbiome — pathways that could help explain why some people with IBD have different microbiomes or disease risk. If validated in trials, FUT2-targeted or...
Identifies macrophage-linked genes (CCL3, CCL4, JUNB) that are strongly upregulated in ulcerative colitis and may help explain immune-cell remodeling in the colon. These genes could serve as biomarkers or starting points...
This trial tests whether people with UC in deep remission can safely stop JAK inhibitor therapy — potentially reducing long-term exposure and associated safety concerns while preserving disease control and quality of...
This Phase 2a trial tested a new investigational drug, tulisokibart, in people with moderately to severely active Crohn’s disease who have not done well on prior therapies — so patients and clinicians watching new...
The study will prospectively evaluate how often dysplasia occurs, how lesions look and behave after endoscopic resection, and what factors predict local or distant recurrence—information that could change surveillance...
The systems view could explain limits of single-cytokine therapies and point toward multi-layer, precision approaches that better match a patient’s specific immune, genetic, and microbial context.
The study links ER stress and defective autophagy to increased claudin-2 and tight-junction dysfunction—mechanisms relevant to barrier loss in IBD. Targeting this pathway could eventually inform therapies to preserve...
Detecting Crohn’s recurrence after bowel surgery is important because recurrence can occur without symptoms. A reliable non-invasive test like intestinal ultrasound could reduce the need for repeated colonoscopies and...
For people with moderate–severe Crohn’s disease who failed anti‑TNF drugs, this trial suggests risankizumab may achieve higher corticosteroid‑free clinical and endoscopic remission than ustekinumab, which could mean...
Perianal fistulas in Crohn's disease significantly affect quality of life, and this study provides an initially validated Spanish tool to measure that impact, enabling better assessment in Spanish-speaking patients and...
Many people with IBD who achieve remission ask about reducing or stopping medication. This review summarises current evidence and highlights that withdrawal carries substantial relapse risk and that decisions should be...
Automated, sequence-robust MRI measures could help standardize detection and localization of perianal anoperineal lesions in Crohn’s disease, which is relevant for diagnosis and management of perianal complications.
This trial is testing a new experimental oral therapy (BRS201) aimed at reducing hydrogen sulfide–related metabolites in people with mild ulcerative colitis. If successful, the drug could represent a novel, non-biologic...
The study investigates how components of exclusive enteral nutrition (EEN), particularly transforming growth factor‑β (TGF‑β), may help restore intestinal barrier function after colitis. That could help explain why EEN...
This research links molecular subtypes of ulcerative colitis to infliximab (anti-TNF) response using an interpretable machine-learning method, which could help identify which patients are more or less likely to respond...
A fungal infection (basidiobolomycosis) can closely mimic IBD and lead to surgery unless biopsy with fungal stains and culture are done; early azole therapy enabled medical cure in this case. Clinicians in endemic areas...
Oxidative stress may help explain some biological drivers of inflammation in Crohn’s disease and ulcerative colitis and could become a target for biomarkers or therapies in the future. Right now, the evidence is...
CMUSE can closely mimic Crohn's disease and may require surgery for diagnosis and symptom relief. Recognizing it can change diagnostic pathways and multidisciplinary management for people with recurrent small-bowel...
A cross‑trust histopathology MDT helped reclassify diagnoses in a substantial proportion of discussed paediatric IBD cases and occasionally changed management or transition planning, which could affect treatment...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring. The original article is from Cureus.
